At the request of Eli Lilly, the IZB organized a second pitchday this year. The goal was to network more closely with the local venture capital scene, and to get to know new Martinsried Campus projects. On November 9, 2017, seven representatives of pharmaceutical and venture capital firms met at the Faculty Club G2B to present the interesting projects of the IZB start-ups and early stage projects.
“We were impressed by the Martinsried Campus and the interesting start-ups at the IZB. The relatively unique combination of the high-quality incubator facilities, experienced leadership at the IZB, and productive relationships with innovators and venture capitalists make this a very attractive place for Eli Lilly. Many of the projects, especially in the early-stage area, fit well with the strategy of Eli Lilly. We will continue to keep a close eye on the location and certainly participate in such events again,” said Dr. Tim Luker, Senior Director of Emerging Technology & Innovation, Global Corporate Development, who was accompanied by Dr. David Moller, Vice President, and Dr. Stephen Curtis, Senior Director at Eli Lilly.
“The following companies presented their projects: Manfred Gröppel, Managing Director of Immunic AG; Dr. Michael Thormann, Managing Director of Origenis GmbH; Claus Schalper, Managing Director of XL-Protein, Nadja Fenn, workgroup Prof. Karl-Peter Hopfner, Gene Center at the Ludwig Maximilian University Munich (LMU), and the team of Moritz Völker-Albert and Prof. Axel Imhof from the Biomedical Center of the LMU. The last thing that Völker-Albert said was: “Now I have successfully completed the first pitchday of my life!“